Proliferation and checkpoint receptor expression changes on T cells are restricted to the tumour
SECONDARY
Amongst other secondary endpoints, multiplex IF analysis showed that sitravatinib monotherapy may be associated with an influx of CD3+ tumour-infiltrating lymphocytes (TILs) in some patients (Supplementary Fig. 